[go: up one dir, main page]

SG10201912369QA - Anti-cd19 antibody formulations - Google Patents

Anti-cd19 antibody formulations

Info

Publication number
SG10201912369QA
SG10201912369QA SG10201912369QA SG10201912369QA SG10201912369QA SG 10201912369Q A SG10201912369Q A SG 10201912369QA SG 10201912369Q A SG10201912369Q A SG 10201912369QA SG 10201912369Q A SG10201912369Q A SG 10201912369QA SG 10201912369Q A SG10201912369Q A SG 10201912369QA
Authority
SG
Singapore
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
SG10201912369QA
Other languages
English (en)
Inventor
Patrick Garidel
Andreas Langer
Martin Hessling
Daniel Weinfurtner
Bodo Brocks
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of SG10201912369QA publication Critical patent/SG10201912369QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10201912369QA 2016-06-27 2017-06-27 Anti-cd19 antibody formulations SG10201912369QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176322 2016-06-27

Publications (1)

Publication Number Publication Date
SG10201912369QA true SG10201912369QA (en) 2020-02-27

Family

ID=56368805

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810429UA SG11201810429UA (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations
SG10201912369QA SG10201912369QA (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201810429UA SG11201810429UA (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Country Status (26)

Country Link
US (2) US11352423B2 (lt)
EP (2) EP3475303B1 (lt)
JP (3) JP2019524671A (lt)
KR (2) KR102533875B1 (lt)
CN (2) CN115998859A (lt)
AU (2) AU2017289085B2 (lt)
CA (1) CA3029137A1 (lt)
CY (1) CY1124521T1 (lt)
DK (1) DK3475303T3 (lt)
ES (1) ES2874640T3 (lt)
HR (1) HRP20210945T1 (lt)
HU (1) HUE054296T2 (lt)
IL (1) IL263764B2 (lt)
LT (1) LT3475303T (lt)
MA (1) MA45450B1 (lt)
MD (1) MD3475303T2 (lt)
MX (1) MX2018016362A (lt)
PL (1) PL3475303T3 (lt)
PT (1) PT3475303T (lt)
RS (1) RS62035B1 (lt)
RU (1) RU2748024C2 (lt)
SG (2) SG11201810429UA (lt)
SI (1) SI3475303T1 (lt)
SM (1) SMT202100317T1 (lt)
WO (1) WO2018002031A1 (lt)
ZA (1) ZA201900483B (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
IL301786B1 (en) 2016-10-28 2025-05-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
PH12022551009A1 (en) 2019-10-31 2023-03-20 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
WO2023215674A1 (en) * 2022-05-03 2023-11-09 Xencor, Inc. Methods for treating lymphoma
EP4572756A1 (en) 2022-08-17 2025-06-25 Incyte Corporation Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024180511A1 (en) * 2023-03-02 2024-09-06 Novetide Ltd. Process for preparation of glp-1 peptides having controlled particle size

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2426468T3 (es) 2005-12-30 2013-10-23 Merck Patent Gmbh Anticuerpos anti-CD19 con inmunogenicidad reducida
US8524867B2 (en) * 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011008843A (es) 2009-02-23 2011-12-14 Glenmark Pharmaceuticals Sa Anticuerpos humanizados que se unen a cd19 y sus usos.
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2688895T3 (es) 2013-03-13 2018-11-07 F. Hoffmann-La Roche Ag Formulaciones con oxidación reducida
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
NZ719036A (en) 2013-09-27 2022-02-25 Genentech Inc Anti-pdl1 antibody formulations
ES2983564T3 (es) * 2013-11-21 2024-10-23 Genmab As Formulación liofilizada de conjugado de anticuerpos y fármaco
SG11201607306PA (en) * 2014-04-07 2016-09-29 Seattle Genetics Inc Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Also Published As

Publication number Publication date
RU2748024C2 (ru) 2021-05-19
DK3475303T3 (da) 2021-05-31
AU2017289085B2 (en) 2024-07-18
JP7603201B2 (ja) 2024-12-20
MX2018016362A (es) 2019-04-22
PL3475303T3 (pl) 2021-12-06
KR20230074823A (ko) 2023-05-31
JP2019524671A (ja) 2019-09-05
HUE054296T2 (hu) 2021-08-30
IL263764A (en) 2019-01-31
US20220213190A1 (en) 2022-07-07
JP2022119854A (ja) 2022-08-17
CN109415440A (zh) 2019-03-01
EP3475303A1 (en) 2019-05-01
WO2018002031A1 (en) 2018-01-04
RS62035B1 (sr) 2021-07-30
EP3909985A1 (en) 2021-11-17
PT3475303T (pt) 2021-06-25
CA3029137A1 (en) 2018-01-04
KR20190021373A (ko) 2019-03-05
IL263764B1 (en) 2024-05-01
JP2024109816A (ja) 2024-08-14
ZA201900483B (en) 2021-06-30
SMT202100317T1 (it) 2021-07-12
EP3475303B1 (en) 2021-04-14
MD3475303T2 (ro) 2021-09-30
LT3475303T (lt) 2021-06-25
KR102533875B1 (ko) 2023-05-18
AU2024205042A1 (en) 2024-08-15
CN109415440B (zh) 2022-12-06
HRP20210945T1 (hr) 2021-09-17
RU2019100221A (ru) 2020-07-28
CY1124521T1 (el) 2022-07-22
US20190322742A1 (en) 2019-10-24
RU2019100221A3 (lt) 2020-11-30
CN115998859A (zh) 2023-04-25
SI3475303T1 (sl) 2021-12-31
MA45450B1 (fr) 2021-04-30
ES2874640T3 (es) 2021-11-05
AU2017289085A1 (en) 2018-12-13
US11352423B2 (en) 2022-06-07
IL263764B2 (en) 2024-09-01
SG11201810429UA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
IL264159A (en) Anti-tim-3 antibodies
IL264502A (en) Anti-CD3 antibody formulations
ZA201900483B (en) Anti-cd19 antibody formulations
IL266143A (en) Antibody structures
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
ZA201701461B (en) Antibody formulations
RS66141B1 (sr) Sastavi antitela
GB201610044D0 (en) Antibodies
GB201616699D0 (en) Antibodies
IL263406A (en) Anti-tnfrs25 antibodies
GB201603291D0 (en) Antibodies
IL264262A (en) Antibodies against interleukin 22 receptors
IL260083B1 (en) Antibody against myl9
GB201622197D0 (en) Antibodies
GB201508257D0 (en) Antibody formulations
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201613158D0 (en) Antibodies
GB201612437D0 (en) Anti-lag-3 antibodies
GB201415526D0 (en) Antibody Formulations
GB201415298D0 (en) Antibody Formulations